Display Settings:   Send to:  Choose Destination See comment in
PubMed Commons below Clin Infect Dis. 2005 Apr 1;40(7):932-40.
Epub 2005 Mar 2.   Author information    • 1Department of
Pediatrics, University of Washington, Seattle, Washington, USA.
zerr@u.washington.edu    Although human herpesvirus 6 (HHV-6) is
known to reactivate during hematopoietic stem cell
transplantation (HSCT), the clinical significance of this
finding is controversial.   We used a quantitative PCR test for
HHV-6 to assay plasma samples prospectively collected from a
cohort of 110 allogeneic HSCT recipients to evaluate the
clinical effects of HHV-6 infection. A retrospective review of
medical records was performed to determine clinical end points.
HHV-6 reactivation occurred in 52 (47%) of the 110 subjects.
Factors that increased the risk of subsequent HHV-6 reactivation
were hematologic malignancy that occurred at a time other than
the first remission (adjusted P = .002), a mismatch in the sexes
of donor and recipient (adjusted P=.